Celsion (CLSN) Tops Q2 EPS by 2c
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Celsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update
August 15, 2016 9:02 AM EDTSignificant Progress in Immuno-oncology and Chemotherapy Clinical Research Complimented with a 20% Reduction in Operating Expenses
Company to Hold Conference Call on Monday, August 15, 2016 at 11:00 a.m. EDT
LAWRENCEVILLE, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter and six month period ended June 30, 2016 and provided an update on its development programs for ThermoDox®, the Companys proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA-based... More
Celsion Corporation Announces Final Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer
August 15, 2016 8:01 AM EDTSubgroup Data Continue to Show a Statistically Significant Improvement in Overall Survival, Consistent With a Two Year Median Survival Benefit Following Treatment with ThermoDox® plus Optimized RFA
Data from the Chinese Cohort of Patients Show Clinically Meaningful Benefit
LAWRENCEVILLE, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced updated results from its final retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer,... More